[Abstract] Angiogenesis, the growth of new blood vessels from pre-existing vessels, is a critical process that occurs during normal development and tumor formation. Targeting tumor angiogenesis by blocking the activity of vascular endothelial growth factor (VEGF) has demonstrated some clinical benefit; nevertheless there is a great need to target additional angiogenic pathways. We have found that the human umbilical vein endothelial cell (HUVEC) fibrin bead sprouting assay (FBA) is a robust and predictive in vitro assay to evaluate the activity of angiogenesis inhibitors. Here, we describe an optimized FBA protocol for the assessment of biological inhibitors of angiogenesis and the automated quantification of key endpoints.
human umbilical vein endothelial cell (HUVEC) fibrin bead sprouting assay (FBA) is a robust and predictive in vitro assay to evaluate the activity of angiogenesis inhibitors. Here, we describe an optimized FBA protocol for the assessment of biological inhibitors of angiogenesis and the automated quantification of key endpoints.
[Background] Angiogenesis, the growth of new blood vessels from pre-existing vessels, is a physiological process that occurs during wound healing and normal development. Angiogenesis is a complex and highly regulated process involving the tight coordination of endothelial cell proliferation, differentiation, migration, matrix adhesion, and cell-to-cell signaling. Angiogenesis is also critically involved in tumor development and metastasis. Indeed, targeting tumor angiogenesis by blocking the activity of vascular endothelial growth factor (VEGF) has demonstrated clinical benefit. Since tumors do eventually develop resistance to VEGF-targeted therapy, there is a great need to target additional angiogenic pathways. We have found that the human umbilical vein endothelial cell (HUVEC) fibrin bead sprouting assay (FBA) (Nakatsu et al., 2007; Nakatsu and Hughes, 2008; Nehls and Drenckhahn, 1995) is a robust and predictive in vitro assay to evaluate the activity of angiogenesis inhibitors. This assay recapitulates key aspects of angiogenesis such as lumen formation, endothelial cell polarization and dependency on stromal cells, and is correlative with the activities of angiogenesis inhibitors as observed in in vivo tumor studies (Figures 1 and 2 b. Let beads settle (~15 min). Aspirate the supernatant using a pipette and wash 3 x 5 min in 50 ml fresh PBS using a rocker at RT. Do not vortex.
c. Aspirate PBS using a pipette and replace with fresh PBS (50 ml) such that the bead concentration is 10 mg/ml or 30,000 beads/ml.
d. Transfer the bead suspension in a siliconized glass bottle.
e. Sterilize the beads by autoclaving for 15 min at 115 °C.
f. Store at 4 °C. Spin cells in a centrifuge, remove supernatant with an aspirator, and adjust cell concentration to 2 x 10 6 cells/ml.
3. Under sterile conditions, place 170 μl bead solution (stock concentration: 30,000 beads/ml) in a FACS tube. This should be ~5,000 beads. Allow beads to settle (do not centrifuge), aspirate the supernatant, and wash the beads in 2 ml of warm EGM-2 medium. Remove media using a pipette and add fresh warm media for a total volume of 2 ml.
4. Add 2 x 10 6 HUVEC (1 ml of 2 x 10 6 cells/ml) to 5,000 beads (in 2 ml) in the FACS tube (total volume 3 ml). Place tube vertically in the incubator. This will be enough for ~20 wells. 1. Add 0.15 Units/ml of aprotinin to 15 ml of fibrinogen solution.
2. Check HUVEC coated beads. Transfer 5 ml of coated beads to a 15 ml conical tube and let the beads settle. Use additional 5 ml of media to wash off beads that are stuck to flask.
www.bio-protocol.org/e1947 3. Let beads settle to the bottom of the tube. Aspirate off media. Re-suspend beads in 1 ml of EGM-2 and transfer to a 1.5 ml centrifuge tube.
4. Wash the beads 2 x with 1 ml of EGM-2, mixing by pipetting up and down very slowly/carefully (beads are fragile) with a P1000 pipette.
5. Add 6.25 μl of thrombin stock solution (50 U/ml) to the center of each well of a 24-well plate.
This will result in 0.625 U/ml once 0.5 ml of fibrinogen/bead suspension is added in the next step.
6. Get fibrinogen/bead mixture into solution by pipetting up and down gently. Add 0.5 ml of fibrinogen/bead suspension to each well. 9. Then incubate at 37 °C and 5% CO2 for 10-15 min.
10. While waiting, trypsinize fibroblasts and re-suspend in EGM adjusted to 1 x 10 6 cell/ml (or 1,000
cells/μl)
Note: Fibroblasts will proliferate, migrate and form a monolayer on the fibrin gel.
11. Prepare the appropriate amount of EGM-2 media containing the angiogenesis inhibitor of choice (aflibercept at 50 μg/ml, Dll4 MAB at 50 μg/ml, Integrin α-6 antibody GoH3 at 10 μg/ml).
12. After incubation, add 1 ml of EGM-2 prepared to each well slowly (drop by drop). If media is added too fast, it could tear the gel.
13. Seed 20 μl of NHLF cell solution (20,000 cells) on top of the clot into each well. Add directly into the center of well and into the media.
14. Replace with fresh EGM-2 medium every other day (day 2, 5, 7, etc.) until desired growth (see notes below) is achieved and capture images accordingly.
Notes:
a. Budding/sprouting should be apparent between day 2 and 4. E. Gel processing and sprout staining for DNA and actin 1. To stop the assay, 500 μl of 2% paraformaldehyde (PFA) is added to the gels for 1 h at 37 °C, followed by overnight incubation at room temperature (RT). Wash twice with PBS.
2. To stain the endothelial sprouts, gels are permeabilized with 500 μl of 0.5% Triton X-100 for 20 min, washed twice with PBS. www.bio-protocol.org/e1947 
